Rohit Gosain, MD

Adverse Event Data from CAPItello-291 in HR+ Breast Cancer

Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.

Key Data from CAPItello-291 in HR+ Breast Cancer

Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.

Biomarker Testing and Prevalence of AKT1/PIK3CA/PTEN Mutations in Breast Cancer

Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.

Rationale and Study Design of CAPItello-291 in HR+ Advanced Breast Cancer

Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.

Overall Survival Update for KEYNOTE-564 in Renal Cell Carcinoma

Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides

AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.

BRCAAway: Novel Hormonal Therapies With PARP inhibitors in mCRPC

A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.

CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC

Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.

Key Takeaways from 2024 ASCO GI Cancers Symposium

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

The Role of ctDNA in Colorectal Cancer

Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

NETTER-2: Lu-177 Dotatate for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

Medical oncologists offer comprehensive insights on the role of circulating tumor DNA in the treatment of patients with colorectal cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

EMERALD-1: Durvalumab/Bevacizumab Plus TACE in Unresectable HCC

Clinical insights on the recent data from the NETTER-2 trial looking at Lu-177 Dotatate in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

CheckMate 8HW: Nivolumab Plus Ipilimumab in MSI-High/dMMR Metastatic Colorectal Cancer

Pamela L. Kunz, MD, and the Oncology Brothers provide insights on the EMERALD-1 trial looking at durvalumab and bevacizumab plus TACE in patients with unresectable, embolization-eligible hepatocellular carcinoma.

Rohit Gosain, MD;Rahul Gosain, MD;Pamela L. Kunz, MD

Key Takeaways from ASH 2023 in Myelofibrosis and AML

Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

Revumenib for Patients With Acute Myeloid Leukemia

Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.

MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis

Medical oncologists discuss the results from the SAVE and AUGMENT-101 clinical trials investigating revumenib in patients with acute myeloid leukemia.

TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis

Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.

Key Takeaways from SABCS 2023 in HER2+ Breast Cancer

Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the TRANSFORM-1 trial investigating navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Rahul Gosain, MD, and Rohit Gosain, MD, the Oncology Brothers

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD

HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.

Daniel Stover, MD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD

Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2+ Early Breast Cancer

Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD

Sub-Analysis from APHINITY on Adjuvant Pertuzumab and Trastuzumab in HER2+ Breast Cancer

Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.

Daniel Stover, MD; Rahul Gosain, MD; and Rohit Gosain, MD, presenting slides

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD

Key Takeaways from SABCS 2023

Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.

Rahul Gosain, MD; Rohit Gosain, MD; and Hope Rugo, MD, presenting slides

TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in HR+/HER2- breast cancer.

Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer

Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.

MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer

Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.

Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer

Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.